The product will be manufactured at Lupin's Pithampur facility, the company said in its BSE filing.
Lupin share price gained nearly a percent intraday on December 20 after the US health regulator approved a drug for treating rheumatic disorders.
The pharma major said it received the approval of the United States Food and Drug Administration (USFDA), to market its Betamethasone Dipropionate Ointment USP (Augmented), 0.05 percent, in that country.
Betamethasone is a generic equivalent of Diprolene ointment of Merck Sharp and Dohme Corp.
The product will be manufactured at Lupin's Pithampur (Unit 3) facility, the company said in its BSE filing.
Betamethasone is a corticosteroid for inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
This drug had annual sales of approximately $22 million in the US, IQVIA MAT data on September 2019 shows.The stock was quoting at Rs 775, up Rs 4.30, or 0.56 percent, at the time of publishing this copy.Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.